2576 (2576) Fair Value & Analysis

Healthcare · Market cap HK$3.8B

2 2576 2576 · HK

PriceHK$6.71

Fair ValueHK$1.71

Upside-74.5%

Quality65/100

Watch 2576 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$1.13 – HK$2.14

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price +60.5% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$3.31 – HK$6.71 · fair‑value band HK$1.13 – HK$2.14 · the HK$6.71 price screens above the HK$1.71 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2576 (2576) currently trades at HK$6.71, while our model-based Fair Value estimate is HK$1.71 — implying the stock looks roughly 74.5% overvalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 2576 generated revenue of HK$513M at a net margin of -8.4%. Revenue declined 3.6% year over year. It earns a return on equity of -4.2%. The balance sheet holds a net cash position of HK$564M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$513M

Revenue growth (YoY) -3.6%

Net margin -8.4%

Return on equity -4.2%

Free cash flow −HK$43.1M FY2025

Operating margin -8.8%

More key figures

EPS (TTM) HK$-0.0400

Net cash HK$564M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2576 reported revenue of HK$499M in FY2025 versus HK$466M in FY2021, a compound +1.7%/yr. Reported net income was −HK$41.7M in FY2025.

Revenue +1.7%/yr

FY21 HK$466M

FY22 HK$549M

FY23 HK$573M

FY24 HK$551M

FY25 HK$499M

Net income

FY21 −HK$480M

FY22 −HK$413M

FY23 −HK$347M

FY24 −HK$215M

FY25 −HK$41.7M

Is 2576 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$153.16	$183.66	+20%
Pro Medicus Limited PME	A$165.64	A$28.02	-83%
BrightSpring Health Services, Inc BTSG	$60.59	$23.87	-61%
Tempus AI, Inc TEM	$48.61	$12.67	-74%
HealthEquity, Inc HQY	$84.61	$79.57	-6%
M3, Inc MTHRY	$5.21	$7.47	+43%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2576 (2576) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$1.71 versus a price of HK$6.71 — about −75% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2576?

Our model-based fair value for 2576 is HK$1.71 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$6.71.

What is the quality score of 2576?

2576 has a Quality Score of 65/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2576 (2576)?

2576 reported trailing-twelve-month revenue of about HK$513M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2576?

The net profit margin of 2576 is about -8.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.